Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as melphalan and dexamethasone, work in different
ways to stop the growth of abnormal plasma cells, either by killing the cells or by stopping
them from dividing. Biological therapies, such as lenalidomide, may stimulate the immune
system in different ways and stop the abnormal plasma cells from growing. Giving melphalan
together with lenalidomide and dexamethasone may be an effective treatment for primary
systemic amyloidosis.
PURPOSE: This phase II trial is studying the side effects and how well giving melphalan
together with lenalidomide and dexamethasone works in treating patients with primary systemic
amyloidosis.